Endometrial Cancer

Cut-away illustration of the uterus with a thickened area of lining
Endometrial cancer begins in the endometrium, the lining of the uterus.
Infographic: lining of the uterus, abnormal bleeding, most common gynecologic cancer
Endometrial cancer starts in the lining of the uterus, often shows as abnormal bleeding, and is the most common gynecologic cancer in the United States.
Histology view of crowded glands in uterine lining tissue
Under the microscope, endometrial cancer shows crowded, irregular glands in the uterine lining.

Table of Contents

  1. Overview
  2. Epidemiology
  3. Pathophysiology
  4. Etiology and Risk Factors
  5. Clinical Presentation
  6. Diagnosis
  7. Treatment
  8. Complications
  9. Prognosis
  10. Prevention
  11. Recent Research and Advances
  12. Key Research Papers
  13. Connections
  14. Featured Videos

1. Overview

Endometrial cancer is cancer of the endometrium — the lining of the uterus (womb) that thickens each month and sheds as a menstrual period. It is the most common gynecologic cancer in the United States, with roughly 67,000 new cases and about 13,000 deaths each year. People often call it “uterine cancer,” and the two terms are used almost interchangeably, because the great majority of cancers that start in the body of the uterus begin in the endometrium.

There is good news and bad news in the same sentence. The good news: about 9 in 10 women with endometrial cancer notice abnormal vaginal bleeding early, which is exactly why most cases are caught at an early, highly curable stage. The bad news: endometrial cancer is one of the few cancers in the U.S. whose incidence AND death rate are both rising, driven largely by the obesity epidemic and an aging population. So the disease is becoming more common even as we get better at treating it.

The single most important idea on this page is a hormone story. Most endometrial cancer is driven by estrogen that is not balanced by progesterone — what doctors call unopposed estrogen. Understanding that one mechanism explains almost every risk factor, every prevention strategy, and the logic behind the most common treatment. We will explain it in plain language below.

2. Epidemiology

Endometrial cancer is the fourth most common cancer in women in the United States and the most common cancer of the female reproductive tract — more common than ovarian and cervical cancer combined. A woman’s lifetime risk is roughly 1 in 36 (about 3%). Most cases are diagnosed after menopause, with a median age around 60–63 years, although a meaningful minority of cases occur in younger women, particularly those with obesity or polycystic ovary syndrome.

What makes endometrial cancer unusual among major cancers is its trajectory. While many cancers (lung, colorectal, stomach) are becoming less deadly over time, endometrial cancer incidence in the U.S. has been rising by roughly 1–2% per year, and — unlike most cancers — mortality is rising too. Two forces drive this: the obesity epidemic (more women carry the metabolic risk factor), and a relative increase in aggressive, non–estrogen-driven subtypes that are harder to treat.

There is a stark and honest racial disparity that deserves to be stated plainly. Black women in the U.S. are diagnosed at similar or slightly lower rates than White women but die from endometrial cancer at roughly twice the rate. The reasons are layered: Black women are more likely to develop the aggressive serous and other high-grade (“non-endometrioid”) subtypes, are more often diagnosed at a later stage, and face unequal access to timely biopsy, specialist surgery, and clinical trials. This gap is one of the widest racial survival gaps in all of oncology, and closing it is an active priority in research and policy.

3. Pathophysiology

To understand endometrial cancer, picture the endometrium as a lawn that responds to two hormones. Estrogen is the fertilizer — it tells the lining to grow and thicken. Progesterone is the gardener — after ovulation it matures the lining, stops the growth, and prepares it either to support a pregnancy or to shed cleanly as a period. In a normal monthly cycle, estrogen builds the lining in the first half and progesterone reins it in during the second half.

Now imagine fertilizer with no gardener. When estrogen acts on the endometrium month after month without progesterone to balance it, the lining keeps proliferating. Over years, that relentless growth can progress through a recognized sequence: normal endometrium → endometrial hyperplasia (overgrowth) → hyperplasia with atypia (overgrowth with abnormal-looking cells) → endometrial cancer. The crucial point: hyperplasia with atypia is a true precancer. Left untreated, a large fraction progresses to or already harbors cancer, which is why it is treated aggressively (see Treatment).

Where does the unopposed estrogen come from in a postmenopausal woman who no longer ovulates? Often from her own body fat. Fat tissue (adipose tissue) is hormonally active. It contains the enzyme aromatase, which converts androgens (made by the adrenal glands and ovaries) into estrogen. More fat means more aromatase, more estrogen, and — because there is no ovulation and therefore no progesterone after menopause — that estrogen is entirely unopposed. This single biochemical fact links obesity directly to endometrial cancer.

Pathologists historically divided endometrial cancer into two clinical types, a framework introduced by Bokhman in 1983 that remains a useful first cut:

This two-type model is honest but simplified. Modern molecular profiling (see Diagnosis and Recent Research) has refined it considerably.

4. Etiology and Risk Factors

Almost every well-established risk factor traces back to the same root: more lifetime exposure to estrogen unopposed by progesterone. Hold that lens up and the list below stops looking random.

Lynch syndrome deserves its own paragraph. It is an inherited condition caused by a fault in one of the DNA mismatch-repair (MMR) genes (MLH1, MSH2, MSH6, PMS2) and accounts for roughly 3% of all endometrial cancers — and a higher share among women diagnosed young. The risk depends on the gene: in a 2011 French study, the risk of endometrial cancer by age 70 was about 54% with an MLH1 fault, 21% with MSH2 and 16% with MSH6, while the risk by age 40 did not exceed 2%; and for many of these women, endometrial cancer is the first cancer they develop — a “sentinel” cancer that can lead to testing of the whole family. Lynch syndrome also dramatically raises the risk of colorectal cancer and others, so identifying it protects not just the patient but her parents, siblings, and children. Because of this, most pathology labs now perform universal MMR/microsatellite-instability testing on every endometrial tumor, and abnormal results trigger referral for genetic counseling and testing. Women diagnosed before age 50, or with a strong family history of colon or uterine cancer, are especially likely to be offered testing.

5. Clinical Presentation

The key fact on this page: any bleeding after menopause is treated as abnormal until proven otherwise. Even a single episode of spotting, even a few drops, even “just once”, is evaluated by doctors. About 90% of women with endometrial cancer have abnormal bleeding as their first and often only symptom, which is precisely why this cancer is so often caught early and cured.

The reassurance: the large majority of postmenopausal bleeding turns out to be benign — thinning of the lining (atrophy), polyps, or hormonal causes. Only a minority is cancer. But there is no way to tell the difference without an evaluation, and waiting only lets a treatable cancer grow. Because postmenopausal bleeding is the first sign in about 9 in 10 women with this cancer, clinics evaluate it as urgent, and prompt evaluation is how most of these cancers are found while still curable.

In premenopausal women, the warning signs are different and easier to overlook because some irregular bleeding is normal. Patterns that warrant evaluation include: bleeding between periods, unusually heavy or prolonged periods, and a marked change in a long-standing pattern — especially in a woman with obesity, polycystic ovary syndrome, infrequent periods, or a family history of Lynch-related cancers. A young woman with polycystic ovary syndrome who goes many months without a period is exactly the person whose endometrium may be quietly overgrowing, and persistent abnormal bleeding in that setting is a recognized warning sign, not “just hormones.”

Other, later symptoms can include watery or blood-tinged vaginal discharge, pelvic pain or pressure, and pain with intercourse — but these usually appear after bleeding has already started.

6. Diagnosis

The work-up for suspected endometrial cancer is relatively quick and mostly done in the office.

Once cancer is confirmed, the pathologist determines the type and grade, and the tumor is tested with molecular and immunohistochemical markers. Two are routine now: MMR/microsatellite-instability testing (to flag Lynch syndrome and to predict response to immunotherapy) and p53 staining (to flag aggressive serous-like tumors). Imaging such as magnetic resonance imaging (MRI) or computed tomography (CT) may be added to assess spread, but endometrial cancer is ultimately surgically staged — the true extent is confirmed at the time of the operation.

7. Treatment

Surgery is the cornerstone. The standard operation is a hysterectomy (removal of the uterus and cervix) plus bilateral salpingo-oophorectomy (removal of both fallopian tubes and ovaries, abbreviated BSO), usually with sentinel lymph node mapping to check whether cancer has reached the lymph nodes.

Importantly — and unlike cervical cancer — minimally invasive surgery (laparoscopic or robotic) is fully appropriate for endometrial cancer. The landmark Gynecologic Oncology Group (GOG) LAP2 trial found that laparoscopic staging had fewer moderate-to-severe complications after surgery than open surgery (14% vs 21%) and far fewer hospital stays longer than 2 days (52% vs 94%). Its later report on cancer outcomes found a 3-year recurrence rate of 11.4% with laparoscopy and 10.2% with open surgery — just short of the trial’s formal test of non-inferiority — and nearly identical 5-year survival (89.8% in both groups). The FIRES trial validated sentinel node mapping: among 36 women whose lymph nodes held cancer and who had at least one sentinel node mapped, the sentinel nodes found the cancer in 35 (sensitivity 97.2%, negative predictive value 99.6%), and at least one sentinel node was mapped in 86% of women. Sentinel mapping spares many women a full lymph-node dissection and its risk of leg swelling (lymphedema). So most women today can have a smaller, gentler operation.

After surgery, treatment is tailored to risk:

Fertility-sparing treatment is possible for a carefully selected group of young women who want to preserve the chance of pregnancy. The criteria are strict: a low-grade (grade 1) endometrioid cancer confined to the lining, with no evidence of deeper invasion or spread on imaging, and a willingness to be monitored closely. Instead of hysterectomy, these women are treated with high-dose progestin therapy — oral progestins and/or a levonorgestrel intrauterine device (IUD) — with repeat biopsies every few months. In pooled data, roughly three-quarters of well-selected women achieve a complete response, but relapse is common (a substantial fraction, often around a third, recur), so this is a temporary, closely watched strategy — not a cure — and hysterectomy is generally recommended once childbearing is complete.

Finally, the precancer matters here too. Endometrial hyperplasia with atypia is most definitively treated by hysterectomy, but in women who want to preserve fertility or who cannot have surgery, progestin therapy — particularly the levonorgestrel IUD — can reverse it in a large share of cases and is a well-established alternative.

8. Complications

Complications come from both the disease and its treatment.

9. Prognosis

Overall, endometrial cancer has a favorable prognosis compared with most cancers, precisely because early bleeding leads to early diagnosis. The honest numbers:

Prognosis depends heavily on type, grade, and molecular profile, not just stage. Serous and clear cell carcinomas and p53-abnormal (copy-number-high) tumors do worse stage-for-stage, while tumors with POLE mutations do remarkably well (see below). And the survival statistics are not experienced equally: the racial disparity described earlier means averages can hide meaningfully worse outcomes for Black women, a gap driven by tumor biology and access rather than by any difference in the women themselves.

10. Prevention

Several of the strongest risk factors are modifiable, and the protective strategies follow directly from the hormone story.

11. Recent Research and Advances

The biggest shift in how doctors think about endometrial cancer came from molecular classification. In 2013, The Cancer Genome Atlas (TCGA) project showed that endometrial cancer is not two types but four distinct molecular groups, each with a different prognosis. A practical, clinic-friendly version of this system (often called ProMisE, the Proactive Molecular Risk Classifier for Endometrial Cancer) now sorts tumors into:

Why does this matter to a patient? Because two tumors that look identical under the microscope can behave completely differently depending on their molecular group — and treatment is increasingly chosen on that basis. The same testing that identifies the immunotherapy-responsive MMRd group also flags Lynch syndrome. The arrival of immunotherapy (dostarlimab in RUBY, pembrolizumab in NRG-GY018, pembrolizumab plus lenvatinib in KEYNOTE-775) represents the first major survival improvement in advanced endometrial cancer in decades, and the benefit is greatest in exactly the molecular group the new testing identifies. Research now focuses on de-escalating treatment for the favorable groups (sparing women unnecessary radiation and chemotherapy) while intensifying it for the aggressive p53-abnormal group.

In 2023 the International Federation of Gynecology and Obstetrics (FIGO) rewrote its staging system for endometrial cancer — the first update since 2009 — adding the tumor’s cell type and, when known, its molecular group to the stage itself. Molecular testing (POLE-mutated, mismatch-repair deficient, no specific molecular profile, p53-abnormal) is encouraged for all endometrial cancers, and in stage I and II disease a p53-abnormal result moves the cancer up a stage while a POLE mutation moves it down.

Key Research Papers

Historical Background

Endometrial cancer played a pivotal role in the history of women’s health and pharmacovigilance. In the 1970s, an epidemic of endometrial cancer followed the popular use of estrogen-only replacement therapy in menopausal women. In 1975, two landmark papers in the New England Journal of Medicine — by Smith and colleagues and by Ziel and Finkle — established that exogenous (estrogen-only) hormone therapy sharply increased endometrial cancer risk. The response — adding progestins to estrogen therapy for women with a uterus — remains standard practice and is one of medicine’s clearest examples of identifying and reversing a drug-caused cancer. In 1983, Bokhman proposed the influential type I / type II framework distinguishing estrogen-driven from non–estrogen-driven tumors. Three decades later, in 2013, The Cancer Genome Atlas reclassified the disease into four molecular subgroups, ushering in today’s era of biology-guided treatment.

  1. Ziel HK, Finkle WD. Increased Risk of Endometrial Carcinoma among Users of Conjugated Estrogens. New England Journal of Medicine. 1975;293(23):1167-1170. — doi:10.1056/NEJM197512042932303
  2. Smith DC, Prentice R, Thompson DJ, Herrmann WL. Association of Exogenous Estrogen and Endometrial Carcinoma. New England Journal of Medicine. 1975;293(23):1164-1167. — doi:10.1056/NEJM197512042932302
  3. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecologic Oncology. 1983;15(1):10-17. — doi:10.1016/0090-8258(83)90111-7
  4. The Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67-73. — doi:10.1038/nature12113
  5. Talhouk A, McConechy MK, Leung S, et al. A clinically applicable molecular-based classification for endometrial cancers. British Journal of Cancer. 2015;113(2):299-310. — doi:10.1038/bjc.2015.190
  6. Crosbie EJ, Kitson SJ, McAlpine JN, et al. Endometrial cancer. The Lancet. 2022;399(10333):1412-1428. — doi:10.1016/S0140-6736(22)00323-3
  7. Lu KH, Broaddus RR. Endometrial Cancer. New England Journal of Medicine. 2020;383(21):2053-2064. — doi:10.1056/NEJMra1514010
  8. Clarke MA, Devesa SS, Harvey SV, Wentzensen N. Hysterectomy-Corrected Uterine Corpus Cancer Incidence Trends and Differences in Relative Survival Reveal Racial Disparities and Rising Rates of Nonendometrioid Cancers. Journal of Clinical Oncology. 2019;37(22):1895-1908. — doi:10.1200/JCO.19.00151
  9. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. The Lancet. 2008;371(9612):569-578. — doi:10.1016/S0140-6736(08)60269-X
  10. Collaborative Group on Epidemiological Studies on Endometrial Cancer. Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies. The Lancet Oncology. 2015;16(9):1061-1070. — doi:10.1016/S1470-2045(15)00212-0
  11. Bonadona V, Bonaiti B, Olschwang S, et al. Cancer Risks Associated With Germline Mutations in MLH1, MSH2, and MSH6 Genes in Lynch Syndrome. JAMA. 2011;305(22):2304-2310. — doi:10.1001/jama.2011.743
  12. Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. The Lancet. 2000;355(9213):1404-1411. — doi:10.1016/s0140-6736(00)02139-5
  13. Nout RA, Smit VT, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. The Lancet. 2010;375(9717):816-823. — doi:10.1016/S0140-6736(09)62163-2
  14. Walker JL, Piedmonte MR, Spirtos NM, et al. Laparoscopy Compared With Laparotomy for Comprehensive Surgical Staging of Uterine Cancer: Gynecologic Oncology Group Study LAP2. Journal of Clinical Oncology. 2009;27(32):5331-5336. — doi:10.1200/JCO.2009.22.3248
  15. Walker JL, Piedmonte MR, Spirtos NM, et al. Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. Journal of Clinical Oncology. 2012;30(7):695-700. — doi:10.1200/JCO.2011.38.8645
  16. Rossi EC, Kowalski LD, Scalici J, et al. A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study. The Lancet Oncology. 2017;18(3):384-392. — doi:10.1016/S1470-2045(17)30068-2
  17. de Boer SM, Powell ME, Mileshkin L, et al. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. The Lancet Oncology. 2018;19(3):295-309. — doi:10.1016/S1470-2045(18)30079-2
  18. de Boer SM, Powell ME, Mileshkin L, et al. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. The Lancet Oncology. 2019;20(9):1273-1285. — doi:10.1016/S1470-2045(19)30395-X
  19. Mirza MR, Chase DM, Slomovitz BM, et al. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. New England Journal of Medicine. 2023;388(23):2145-2158. — doi:10.1056/NEJMoa2216334
  20. Powell MA, Bjørge L, Willmott L, et al. Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial. Annals of Oncology. 2024;35(8):728-738. — doi:10.1016/j.annonc.2024.05.546
  21. Eskander RN, Sill MW, Beffa L, et al. Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer. New England Journal of Medicine. 2023;388(23):2159-2170. — doi:10.1056/NEJMoa2302312
  22. Makker V, Colombo N, Casado Herráez A, et al. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer. New England Journal of Medicine. 2022;386(5):437-448. — doi:10.1056/NEJMoa2108330
  23. Berek JS, Matias-Guiu X, Creutzberg C, et al. FIGO staging of endometrial cancer: 2023. Journal of Gynecologic Oncology. 2023;34(5):e85. — doi:10.3802/jgo.2023.34.e85

PubMed Topic Searches

Endometrial cancer is a fast-moving research field, with active work on molecular classification, immunotherapy, fertility-sparing care, and the racial survival gap. The PubMed searches below open current peer-reviewed literature in a new tab so you can explore the evidence yourself.

  1. PubMed: Endometrial cancer treatment
  2. PubMed: Endometrial cancer molecular classification
  3. PubMed: Endometrial cancer immunotherapy (dostarlimab)
  4. PubMed: Endometrial cancer and obesity
  5. PubMed: Endometrial cancer and Lynch syndrome
  6. PubMed: Endometrial hyperplasia progestin treatment
  7. PubMed: Endometrial cancer fertility-sparing therapy
  8. PubMed: Endometrial cancer sentinel lymph node
  9. PubMed: Endometrial cancer racial disparities
  10. PubMed: Endometrial cancer postmenopausal bleeding
  11. PubMed: Endometrial cancer, oral contraceptives, prevention
  12. PubMed: Serous endometrial carcinoma and p53

Back to Table of Contents

Connections

Back to Table of Contents